HDV Insulin - Diasome Pharmaceuticals

Drug Profile

HDV Insulin - Diasome Pharmaceuticals

Alternative Names: HDV Humalog; HDV Insulin Lispro; HDV-B; HDV-I; HDV-Insulin; Hepatic Directed Vesicle Insulin Lispro; Oral HDV-I

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator Diasome Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 May 2017 Diasome Pharmaceuticals plans a phase II trial for Type-1 diabetes mellitus (Treatment-experienced, In adults, In the elderly) in USA (NCT03156361)
  • 18 Apr 2017 Diasome Pharmaceuticals initiates a phase II trial in Type-1 diabetes mellitus in USA (NCT03096392)
  • 11 Apr 2017 Diasome Pharmaceuticals plans a randomised, double-blind, active comparator controlled, multiple dose phase II trial for Type-1 diabetes mellitus in USA (SC, Injection) (NCT03096392)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top